Product Reports Resources Pricing Login Book a demo

MyoKardia

Biotech & Life Sciences · San Francisco, United States · Founded 2012 · IPO 2015

Develops novel, small molecule therapeutics that address key clinical needs of patients with genetic heart diseases

Valuation $13B
Revenue $26M
Power Law Decacorn$10B+ valuation tier Colt$25–100M revenue
Featured in
News Kardigan prices $400M IPO, extending biotech's hot streak Jun 19, 2026

Investors

10 investors on MyoKardia's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 6 investors entered at this stage
Cowen Group
Casdin Capital
Sanofi
BridgeBio
Cormorant Asset Management
Third Rock Ventures
Series B+ 4 investors entered at this stage
University of Colorado Boulder
Stanford University
Harvard University
Harvard Medical School

MyoKardia mafia

Startups founded by MyoKardia alumni

Former MyoKardia employees who went on to start their own companies. Sorted by Dealroom signal score.

KardiganEst. 2023
Jay EdelbergUnited States
Signal score94
BridgeBioEst. 2014
Neil KumarUnited States
Signal score93
AlumisEst. 2021
June LeeUnited States
Signal score91
HealthExEst. 2022
Priyanka Agarwal, MD, MBAUnited States
Signal score90
Maze TherapeuticsEst. 2018
Eric GreenUnited States
Signal score81
WithMe HealthEst. 2018
Ash DamleUnited States
Signal score79
Global Blood TherapeuticsEst. 2012
CHCharles HomcyUnited States
Signal score64
KainomyxEst. 2019
Suman NagUnited States
Signal score55

Book a demo to explore the full alumni network →

Global footprint

Where MyoKardia has talent and traffic

Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Talent graph

The shape of MyoKardia's talent

Dealroom maps MyoKardia's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock MyoKardia's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$44M patent portfolio · 31 active families

Estimated portfolio value
$44M
0.33% of market cap · 163.6× smaller than top peer Janssen Vaccines ($7.1B)
31 active patent families
Where MyoKardia innovates CardiomyopathyDiastolic functionHeart disease disorderHypertrophic cardiomyopathyLeft Ventricles

Where MyoKardia concentrates vs peers

Each axis is a top-10 topic across MyoKardia and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about MyoKardia

An AI-synthesized read of the highest-engagement posts about MyoKardia on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See MyoKardia on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles